超声靶向微泡破坏增强多柔比星在小鼠肝细胞癌模型中的抗肿瘤疗效
研究在小鼠肝细胞癌(HEP-G2-RFP肿瘤)模型中,观察携抗VEGFR2抗体的靶向微泡经超声破坏(UTMD)能否增强多柔比星(DOX)疗效。DOX联合UTMD自治疗第7天起抑制肿瘤生长,早于单用Visistar VEGFR2或单用DOX的第11天;联合组肿瘤体积和重量显著低于单药组(p < 0.05),抗血管生成和凋亡指数最高。
要点
- DOX联合UTMD自治疗第7天起抑制肿瘤生长,单用Visistar VEGFR2或单用DOX自第11天起才出现抑制。
- DOX联合UTMD的肿瘤体积和肿瘤重量显著低于单用DOX(p < 0.05)和单用Visistar VEGFR2(p < 0.05)。
- DOX联合UTMD对肿瘤血管生成的抑制作用和凋亡指数均高于单用DOX和单用Visistar VEGFR2。
核心结论
- UTMD靶向微泡可显著增强DOX在小鼠肝细胞癌模型中的抗肿瘤效应,抑制血管生成并诱导肿瘤细胞凋亡。
研究设计与样本
- 研究为小鼠肝细胞癌模型实验,使用携带HEP-G2-RFP肿瘤的小鼠。
- 干预分组包括Visistar VEGFR2联合超声照射、单用DOX、DOX联合UTMD,以及单用Visistar VEGFR2。
- 靶向微泡为携抗血管内皮生长因子受体2(anti-VEGFR2)抗体者。
关键影像表现/征象
- DOX联合UTMD组自治疗第7天起出现肿瘤生长抑制,单用Visistar VEGFR2组和单用DOX组自第11天起才出现抑制。
- DOX联合UTMD组的肿瘤体积和肿瘤重量显著低于单用DOX组(p < 0.05)和单用Visistar VEGFR2组(p < 0.05)。
- DOX联合UTMD组对肿瘤血管生成的抑制作用最强,凋亡指数最高,均高于单用DOX组和单用Visistar VEGFR2组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The aim of the study described here was to investigate whether ultrasound-mediated microbubble destruction (UTMD) of targeted microbubbles conjugated with an anti-vascular endothelial growth factor receptor 2 (anti-VEGFR2) antibody can enhance the therapeutic effect of doxorubicin (DOX) on a mouse hepatocellular carcinoma (HCC) model bearing HEP-G2-RFP tumors. The growth of liver tumors in mice was inhibited by using Visistar VEGFR2 plus ultrasound irradiation and by DOX alone. DOX plus UTMD had an inhibitory effect on tumor growth beginning on the seventh day of treatment, while Visistar VEGFR2 alone and DOX alone had inhibitory effects beginning on the 11th day. DOX + UTMD significantly decreased tumor volume and tumor weight compared with DOX alone (p < 0.05) and Visistar VEGFR2 alone (p < 0.05). Compared with DOX alone and Visistar VEGFR2 alone, DOX + UTMD had the highest inhibitory effect on tumor angiogenesis and the highest apoptosis index. UTMD-targeted microbubbles can significantly enhance the antitumor effect of DOX on a mouse HCC model, inhibit angiogenesis and induce apoptosis in tumor cells.
引用
- Wu Y, Sun T, Tang J, et al. Ultrasound-Targeted Microbubble Destruction Enhances the Antitumor Efficacy of Doxorubicin in a Mouse Hepatocellular Carcinoma Model. Ultrasound Med Biol. 2019. PMID: 31882167. doi:10.1016/j.ultrasmedbio.2019.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。